Clinical Trial Update: A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the safety and tolerability of fezolinetant for relief of vasomotor symptoms associated with menopause has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hot Flashes

Drugs mentioned

• Fezolinetant (fezolinetant)

Snippet

Sponsor: Astellas Pharma China, Inc. | Conditions: Hot Flashes | Phase 3 | Status: COMPLETED